bluebird bio (Nasdaq: BLUE), a clinical-stage biotechnology company focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy, today announced that Mark Vachon has joined the company’s board of directors.
“We are delighted to welcome Mr. Vachon to our board,” said Nick Leschly, chief bluebird. “Mark’s extensive global experience across healthcare in both general management and financial leadership positions will be invaluable to bluebird as we look to grow our business and potentially introduce innovative gene therapies to treat blood disorders, adrenoleukodystrophy and cancers.”
Help employers find you! Check out all the jobs and post your resume.
